Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artesunate + mefloquine fixed-dose combination for uncomplicated Plasmodium falciparum malaria in India
ISRCTN70618692Phase 3Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of artesunate and mefloquine in Malaria, sponsored by Drugs for Neglected Diseases initiative. Primary endpoint: PCR-corrected adequate clinical and parasitological response on day 63. Started Dec 2007; status: completed.
02
Drugs
artesunatemefloquine
03
Conditions
Malaria
Beyond the preview
Go deeper on ISRCTN70618692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN70618692.